Drug Discovery

The U.S. Department of Energy's Argonne National Laboratory has been awarded two substantial grants totaling up to $21.7 million from the Advanced Research Projects Agency for Health (ARPA-H), a branch of the Department of Health and Human Services. These significant funds are poised to

Imagine facing a post-antibiotic era where previously manageable infections become deadly due to rampant multidrug-resistant bacteria. This emerging threat to global health has pushed scientists to innovate to avert a crisis. The National Institutes of Health (NIH) has awarded $3.96 million to

The development and review timelines for new drugs are critical in addressing the immediate medical needs of patients with serious conditions. In this context, the United States Food and Drug Administration (FDA)’s Fast Track and Accelerated Approval pathways play a pivotal role. These regulatory f

In recent years, a noticeable shift has emerged in the realm of clinical cancer research, with pharmaceutical companies now playing a dominant role in funding and conducting trials. This transformation is evident in the stark contrast between industry and federal sponsorships. Between 2018 and

The rise of artificial intelligence (A.I.) in the pharmaceutical industry signifies a transformative period, placing unprecedented power in the hands of tech-driven drug discovery and igniting debates about innovation, control, and patient safety. Subject to regulatory scrutiny, the FDA has

The landscape of Alzheimer’s disease (AD) diagnosis and treatment is undergoing a significant transformation thanks to the groundbreaking Simoa® technology by Quanterix. This ultra-sensitive immunoassay platform is reshaping how biomarkers are identified and validated, offering new possibilities fo